Literature DB >> 31054778

Somatic mutation of LRP1B is associated with tumor mutational burden in patients with lung cancer.

Shaowei Lan1, Hui Li1, Ying Liu2, Lixia Ma2, Xianhong Liu2, Yan Liu1, Shi Yan1, Ying Cheng3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31054778     DOI： 10.1016/j.lungcan.2019.04.025

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


× No keyword cloud information.
  12 in total

1.  Somatic Mutation Profiling of Intrahepatic Cholangiocarcinoma: Comparison between Primary and Metastasis Tumor Tissues.

Authors:  Shi-Feng Xu; Yuan Guo; Xin Zhang; Xiao-Dan Zhu; Ning Fan; Zhi-Lei Zhang; Gui-Bing Ren; Wei Rao; Yun-Jin Zang
Journal:  J Oncol       Date:  2020-09-17       Impact factor: 4.375

2.  Distinct mutational backgrounds and clonal architectures implicated prognostic discrepancies in small-cell carcinomas of the esophagus and lung.

Authors:  Zhengbo Song; Yueping Liu; Guoping Cheng; Lianpeng Chang; Zicheng Yu; Ming Chen; Gang Chen
Journal:  Cell Death Dis       Date:  2021-05-12       Impact factor: 8.469

3.  Targeted Sequencing Analysis of Predominant Histological Subtypes in Resected Stage I Invasive Lung Adenocarcinoma.

Authors:  Yan Li; Yan Tan; Song Hu; Jun Xie; Zhantao Yan; Xian Zhang; Yun Zong; Han Han-Zhang; Qing Li; Chong Li
Journal:  J Cancer       Date:  2021-04-02       Impact factor: 4.207

4.  Genomic profiles and tumor immune microenvironment of primary lung carcinoma and brain oligo-metastasis.

Authors:  Zhengbo Song; Ling Yang; Zhipeng Zhou; Pansong Li; Wenxian Wang; Guoping Cheng; Rongrong Chen; Lianpeng Chang; Yiping Zhang; Yanfang Guan; Xuefeng Xia; Xin Yi; Rongrong Zhou; Ming Chen
Journal:  Cell Death Dis       Date:  2021-01-21       Impact factor: 8.469

5.  [Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer].

Authors: 
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-11-20

6.  Assessment of POLE and POLD1 mutations as prognosis and immunotherapy biomarkers for stomach adenocarcinoma.

Authors:  Mingyu Zhu; Haiyan Cui; Lu Zhang; Kuo Zhao; Xiaochen Jia; Hao Jin
Journal:  Transl Cancer Res       Date:  2022-01       Impact factor: 1.241

7.  LRP1B is a Potential Biomarker for Tumor Immunogenicity and Prognosis of HCC Patients Receiving ICI Treatment.

Authors:  Yang Cheng; Rui Tang; Yun Zhu; Xiangzhao Li; Biao Wang; Yanling Cheng; Shuzhe Xiao; Penghui Sun; Wenxuan Yu; Cheng Li; Xinsheng Lin
Journal:  J Hepatocell Carcinoma       Date:  2022-03-22

8.  Development of a 5-Gene Signature to Evaluate Lung Adenocarcinoma Prognosis Based on the Features of Cancer Stem Cells.

Authors:  Renping Wan; Hongliang Liao; Jingting Liu; Lin Zhou; Yingqiu Yin; Tianhao Mu; Jie Wei
Journal:  Biomed Res Int       Date:  2022-04-16       Impact factor: 3.246

9.  Genomic and transcriptomic profiling of hepatoid adenocarcinoma of the stomach.

Authors:  Ziyang Liu; Anqiang Wang; Yingying Pu; Zhongwu Li; Ruidong Xue; Chong Zhang; Xiao Xiang; Jian-Yu E; Zhaode Bu; Fan Bai; Jiafu Ji
Journal:  Oncogene       Date:  2021-07-30       Impact factor: 9.867

10.  LRP1B mutation: a novel independent prognostic factor and a predictive tumor mutation burden in hepatocellular carcinoma.

Authors:  Fahui Liu; Wanyun Hou; Jiadong Liang; Lilan Zhu; Chunying Luo
Journal:  J Cancer       Date:  2021-05-13       Impact factor: 4.207
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.